Paper39280671
Are primary tumors suitable for biomarker-guided treatment of metastatic urothelial cancer?
Scholtes MP and 4 others. Transl Androl Urol, 2024. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Are primary tumors suitable for biomarker-guided treatment of metastatic urothelial cancer? Papers, record 39280671. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39280671
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Are primary tumors suitable for biomarker-guided treatment of metastatic urothelial cancer?
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment on | 37031005 | Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution. | https://conductscience.org/library/papers/37031005 |
Source PubMed
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37031005 | Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution. | Eur Urol | 2024 | https://conductscience.org/library/papers/37031005 | PubMed |
| 2 | 38196202 | Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts. | Histopathology | 2024 | https://conductscience.org/library/papers/38196202 | PubMed |
| 3 | 36372626 | Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition. | Eur Urol | 2023 | https://conductscience.org/library/papers/36372626 | PubMed |
| 4 | 30003574 | Concordance of PD-L1 expression in matched urothelial bladder cancer specimens. | Histopathology | 2018 | https://conductscience.org/library/papers/30003574 | PubMed |
| 5 | 31563503 | A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. | Eur Urol | 2020 | https://conductscience.org/library/papers/31563503 | PubMed |
| 6 | 32031899 | EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. | J Clin Oncol | 2020 | https://conductscience.org/library/papers/32031899 | PubMed |
| 7 | 36543146 | Genomic heterogeneity as a barrier to precision oncology in urothelial cancer. | Cell Rep | 2022 | https://conductscience.org/library/papers/36543146 | PubMed |
| 8 | 30007816 | Evolution of PD-1 and PD-L1 Gene and Protein Expression in Primary Tumors and Corresponding Liver Metastases of Metastatic Bladder Cancer. | Eur Urol | 2018 | https://conductscience.org/library/papers/30007816 | PubMed |
| 9 | 33929895 | TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/33929895 | PubMed |
| 10 | 37516671 | Letter to the editor for the article "Molecular urothelial tumor cell subtypes remain stable during metastatic evolution". | World J Urol | 2023 | https://conductscience.org/library/papers/37516671 | PubMed |
| 11 | 37268487 | Re: Alexander Cox, Niklas Klümper, Johannes Stein, et al. Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.03.020. | Eur Urol | 2023 | https://conductscience.org/library/papers/37268487 | PubMed |
| 12 | 34261585 | PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue? | Urol Oncol | 2021 | https://conductscience.org/library/papers/34261585 | PubMed |
| 13 | 35086719 | Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. | Eur Urol | 2022 | https://conductscience.org/library/papers/35086719 | PubMed |
| 14 | 35216942 | TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. | Eur Urol Oncol | 2022 | https://conductscience.org/library/papers/35216942 | PubMed |
| 15 | 27091807 | Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. | Ann Oncol | 2016 | https://conductscience.org/library/papers/27091807 | PubMed |
| 16 | 38020299 | Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer. | Oncol Lett | 2023 | https://conductscience.org/library/papers/38020299 | PubMed |
| 17 | 34861372 | Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. | Ann Oncol | 2022 | https://conductscience.org/library/papers/34861372 | PubMed |
| 18 | 36534531 | Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance. | Clin Cancer Res | 2023 | https://conductscience.org/library/papers/36534531 | PubMed |
| 19 | 37870920 | Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. | N Engl J Med | 2023 | https://conductscience.org/library/papers/37870920 | PubMed |
| 20 | 27749842 | Clonal evolution of chemotherapy-resistant urothelial carcinoma. | Nat Genet | 2016 | https://conductscience.org/library/papers/27749842 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39280671
GET https://conductscience.org/api/papers/v1/39280671/references?page=2